Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Equity Average (2016 - 2026)

Gyre Therapeutics has reported Equity Average over the past 15 years, most recently at $122.1 million for Q4 2025.

  • Quarterly Equity Average rose 50.93% to $122.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $122.1 million through Dec 2025, up 50.93% year-over-year, with the annual reading at $102.8 million for FY2025, 166.09% up from the prior year.
  • Equity Average was $122.1 million for Q4 2025 at Gyre Therapeutics, up from $115.7 million in the prior quarter.
  • Over five years, Equity Average peaked at $122.1 million in Q4 2025 and troughed at $43.3 million in Q1 2022.
  • The 5-year median for Equity Average is $79.1 million (2023), against an average of $78.0 million.
  • Year-over-year, Equity Average tumbled 51.96% in 2022 and then skyrocketed 72.79% in 2023.
  • A 5-year view of Equity Average shows it stood at $60.1 million in 2021, then decreased by 15.48% to $50.8 million in 2022, then decreased by 2.29% to $49.6 million in 2023, then skyrocketed by 62.99% to $80.9 million in 2024, then soared by 50.93% to $122.1 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Equity Average are $122.1 million (Q4 2025), $115.7 million (Q3 2025), and $116.9 million (Q2 2025).